[go: up one dir, main page]

EA200401081A1 - Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro - Google Patents

Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro

Info

Publication number
EA200401081A1
EA200401081A1 EA200401081A EA200401081A EA200401081A1 EA 200401081 A1 EA200401081 A1 EA 200401081A1 EA 200401081 A EA200401081 A EA 200401081A EA 200401081 A EA200401081 A EA 200401081A EA 200401081 A1 EA200401081 A1 EA 200401081A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hcv
human antibody
directed against
neutralizing activity
vitro
Prior art date
Application number
EA200401081A
Other languages
English (en)
Other versions
EA009861B1 (ru
Inventor
Роберто Буриони
Original Assignee
Роберто Буриони
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Роберто Буриони filed Critical Роберто Буриони
Publication of EA200401081A1 publication Critical patent/EA200401081A1/ru
Publication of EA009861B1 publication Critical patent/EA009861B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к человеческому антителу или его функциональным фрагментам, направленному против гликопротеина E2 вируса HCV, способному проявлять нейтрализующую активность in vivo; к композиции для терапии против вируса HCV, заключающей в себе терапевтически эффективное количество антитела; к композиции для местного применения в виде геля, крема, мази и вагинальных свечей; к применению антитела для создания вакцин против вируса HCV.Отчет о международном поиске был опубликован 2003.12.24.
EA200401081A 2002-01-30 2003-01-29 Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro EA009861B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
PCT/IT2003/000032 WO2003064473A2 (en) 2002-01-30 2003-01-29 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity

Publications (2)

Publication Number Publication Date
EA200401081A1 true EA200401081A1 (ru) 2005-10-27
EA009861B1 EA009861B1 (ru) 2008-04-28

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401081A EA009861B1 (ru) 2002-01-30 2003-01-29 Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro

Country Status (17)

Country Link
US (2) US20050084845A1 (ru)
EP (1) EP1476468B9 (ru)
JP (1) JP4287280B2 (ru)
KR (1) KR101002791B1 (ru)
CN (1) CN1856508A (ru)
AT (1) ATE407147T1 (ru)
AU (1) AU2003208000B2 (ru)
CA (1) CA2474801C (ru)
DE (1) DE60323333D1 (ru)
DK (1) DK1476468T3 (ru)
EA (1) EA009861B1 (ru)
ES (1) ES2314179T3 (ru)
IT (1) ITRM20020049A1 (ru)
NZ (1) NZ534922A (ru)
RU (1) RU2004126238A (ru)
WO (1) WO2003064473A2 (ru)
ZA (1) ZA200406187B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
AU2008224060A1 (en) * 2007-03-06 2008-09-12 Ribovax Biotechnologies S.A. Antibodies specific for Rubella Virus
AU2008280057A1 (en) 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Antibody having inhibitory activity on infection with hepatitis C virus (HCV), and use thereof
CA2708740C (en) * 2007-12-17 2017-07-18 Medical Research Council Technology Hepatitis c virus antibodies
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2495256A4 (en) 2009-10-30 2013-09-25 Toray Industries ANTIBODIES HAVING INHIBITION ACTIVITY OF HEPATITIS C VIRUS (HCV) INFECTION AND USE THEREOF
AU2011223906B2 (en) 2010-03-01 2015-06-25 Vincent Agnello Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
CN118459596A (zh) 2019-12-27 2024-08-09 凯奥目生物科学株式会社 抗cdcp1抗体
EP4215211A4 (en) 2020-09-02 2024-10-30 The University of Tokyo TUMOR IMMUNE MICROENVIRONMENT REGULATOR AND ITS PREVENTIVE, THERAPEUTIC OR DIAGNOSTIC USE
WO2024024565A1 (ja) 2022-07-28 2024-02-01 国立大学法人 東京大学 ニューロトリミンの機能阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097172A1 (en) * 1998-07-21 2001-05-09 Genmab A/S Anti hepatitis c virus antibody and uses thereof
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001273363A1 (en) 2000-07-12 2002-01-21 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
EP1355947A2 (en) * 2000-12-01 2003-10-29 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c

Also Published As

Publication number Publication date
US7727529B2 (en) 2010-06-01
AU2003208000B2 (en) 2010-05-20
ITRM20020049A1 (it) 2003-07-30
EA009861B1 (ru) 2008-04-28
WO2003064473A2 (en) 2003-08-07
ATE407147T1 (de) 2008-09-15
NZ534922A (en) 2008-07-31
RU2004126238A (ru) 2005-04-20
KR20040077745A (ko) 2004-09-06
CA2474801A1 (en) 2003-08-07
DE60323333D1 (de) 2008-10-16
CA2474801C (en) 2012-03-20
KR101002791B1 (ko) 2010-12-21
JP4287280B2 (ja) 2009-07-01
CN1856508A (zh) 2006-11-01
DK1476468T3 (da) 2009-01-19
EP1476468A2 (en) 2004-11-17
WO2003064473A3 (en) 2003-12-24
EP1476468B9 (en) 2009-04-08
EP1476468B1 (en) 2008-09-03
US20080241162A1 (en) 2008-10-02
ES2314179T3 (es) 2009-03-16
JP2005531286A (ja) 2005-10-20
US20050084845A1 (en) 2005-04-21
ZA200406187B (en) 2006-06-28
ITRM20020049A0 (it) 2002-01-30

Similar Documents

Publication Publication Date Title
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
KR950005327A (ko) 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
BRPI0412245A (pt) anticorpos de rg1 e usos destes
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
DE69942148D1 (de) Gebrauch von bispezifischen antikörpern in diagnose und therapie
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
DE60238782D1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
ATE457177T1 (de) Kombinationstherapie zur behandlung respiratorischer krankheiten mittels antikörper und anti-entzündungs wirkstoffe
EP1411962A4 (en) TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
EA200400134A1 (ru) Терапевтический агент
MY141459A (en) Recombinant anti-idiotypic antibodies
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment